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Abstract
Repeated administration of haloperidol (HAL) and olanzapine (OLZ) causes a progressively enhanced disruption of the conditioned avoidance response (CAR) and a progressively enhanced inhibition of phencyclidine (PCP)-induced hyperlocomotion in rats (termed antipsychotic
sensitization). Both actions are thought to reflect intrinsic antipsychotic activity. The present study examined the extent to which antipsychotic-induced sensitization in one model (e.g. CAR) can be transferred or maintained in another (e.g. PCP hyperlocomotion) as a means of
investigating the contextual and behavioral controls of antipsychotic sensitization. Well-trained male Sprague-Dawley rats were first repeatedly tested in the CAR or the PCP (3.2 mg/kg, subcutaneously) hyperlocomotion model under HAL or OLZ for 5 consecutive days. Then they
were switched to the other model and tested for the expression of sensitization. Finally, all rats were switched back to the original model and
retested for the expression of sensitization. Repeated HAL or OLZ treatment progressively disrupted avoidance responding and decreased
PCP-induced hyperlocomotion, indicating a robust sensitization. When tested in a different model, rats previously treated with HAL or OLZ
did not show a stronger inhibition of CAR-induced or PCP-induced hyperlocomotion than those treated with these drugs for the first time;
however, they did show such an effect when tested in the original model in which they received repeated antipsychotic treatment. These findings suggest that the expression of antipsychotic sensitization is strongly influenced by the testing environment and/or selected behavioral response under certain experimental conditions. Distinct contextual cues and behavioral responses may develop an association with unconditional drug effects through a Pavlovian conditioning process. They may also serve as occasion setters to modulate the expression of sensitized
responses. As antipsychotic sensitization mimics the clinical effects of antipsychotic treatment, understanding the neurobiological mechanisms
of antipsychotic sensitization and its contextual control would greatly enhance our understanding of the psychological and neurochemical nature of antipsychotic treatment in the clinic.
Keywords: behavioral sensitization, conditioned avoidance response, haloperidol, olanzapine, phencyclidine, rat, time course of antipsychotic
effect

tipsychotic effects due to repeated drug administration is
termed as antipsychotic sensitization. This behavioral pattern is consistent with clinical observations showing that
antipsychotic action increases in magnitude with repeated
treatment over time (Agid et al., 2003, 2006; Kapur et al.,
2005; Leucht et al., 2005; Emsley et al., 2006; Glick et al.,
2006; Raedler et al., 2007).
In comparison with extensive research on behavioral
sensitization induced by psychotomimetic drugs (e.g. amphetamine, cocaine, PCP, etc.; Robinson and Becker, 1986;
Pierce and Kalivas, 1997), antipsychotic sensitization, especially the type induced by atypical antipsychotics (e.g.
OLZ, clozapine, risperidone) is relatively new and less
well understood. This situation is peculiar, given the
fact that anti psychotics, such as drugs of abuse, are often taken repeatedly by people for a prolonged period of
time, and antipsychotic sensitization is thought to be an
important mechanism supporting the maintenance of the
antipsychotic effect (Li et al., 2007). Thus, antipsychotic
sensitization should have received more attention than it

Introduction
The conditioned avoidance response (CAR) and phencyclidine (PCP)-induced hyperlocomotion are two widely
used animal models for the study of antipsychotic drugs.
Both models have high predictive validity for antipsychotic efficacy, as all clinically approved anti psychotics
[e.g. haloperidol (HAL), olanzapine (OLZ), and risperidone]. but not other classes of psychotherapeutic drugs
(e.g. anxiolytics, antidepressants), selectively disrupt
avoidance responding, and inhibit the PCP-induced increase in motor activity upon acute administration (Gleason and Shannon, 1997; Li et al., 2004b). More importantly,
both models are capable of capturing the time course of
antipsychotic treatment in the clinic. With repeated drug
administration, anti psychotics progressively enhance
their disruption of avoidance responding (Li et al., 2009a,
2009b, 2010; Mead and Li, 2010) and their inhibition of
PCP-induced hyperlocomotion over the drug treatment
period (Sun et al., 2009). This progressive increase in an66
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currently has. One major issue that may have contributed
to this lack of attention is the difficulty in demonstrating
its existence. For example, in studies using the prepulse
inhibition paradigm, behavioral sensitization has never
been consistently established among different antipsychotics (Geyer et al., 2001; Li et al., 2011a).
As repeated antipsychotic treatment induces sensitization in both the CAR and the PCP hyperlocomotion models, and both sensitizations putatively reflect the same
antipsychotic activity over time, one interesting and critically important question is whether antipsychotic-induced sensitization is situation specific. In other words,
could the antipsychotic-induced sensitization in one
model (e.g. CAR) be transferred or maintained in another
model (e.g. PCP hyperlocomotion)? We postulated that
studying across-model transfer of antipsychotic sensitization would allow us to investigate the contextual and
behavioral controls of antipsychotic sensitization. If antipsychotic sensitization results from inevitable neurobiological adaptations produced by the direct pharmacological actions of the drug (Tarsy and Baldessarini, 1974), it
should be transferrable across models and suggests that
contextual and behavioral variables have little influence
on the development of antipsychotic sensitization. In contrast, if the context and the behaviors associated with
drug administration have a powerful control on the expression of antipsychotic sensitization, it should not be
transferrable between models.
The present study addressed this question. We tested
HAL and OLZ, two representative drugs for typical and
atypical antipsychotics, and examined bidirectional transfer between the CAR and the PCP models. Our general
approach was to induce behavioral sensitization in one
model through repeated drug administration, then to test
its expression in another model, and finally to retest its
expression back in the first model. Our results showed
that HAL and OLZ sensitization in both models only
manifested itself when the induction condition was the
same as the test condition. These results are in general
agreement with research on psychomotor sensitization,
which also shows that the expression of behavioral sensitization is greatly impacted by contextual cues (Vezina
and Stewart, 1984; Anagnostaras and Robinson, 1996;
Robinson et al., 1998) and selected behavior responses
(Ohmori et al., 2000).
Methods
Subjects
Adult male Sprague-Dawley rats (226-250 g upon arrival,
Charles River, Portage, Michigan, USA) were used. They
were housed two per cage in 48.3 × 26.7 × 20.3-cm transparent polycarbonate cages under 12-h light/dark conditions (light on between 6:30 a.m. and 6:30 p.m.). Room
temperature was maintained at 22 ± 1°C with a relative
humidity of 45-60%. Food and water were freely avail-
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able. Subjects were allowed at least 1 week of habituation to the animal facility before being used in experiments. All procedures were approved by the Institutional
Animal Care and Use Committee at the University of
Nebraska-Lincoln.
Drugs and choice of doses
The injection solution of HAL (5.0 mg/ml ampoules;
Shanghai Xudong Haipu Pharmaceutical Co., Ltd, Shanghai, China) was obtained by mixing the stock with sterile water. OLZ (a gift from the National Institute of Mental Health Drug Supply Program) was dissolved in 1.0%
glacial acetic acid in distilled water. PCP hydrochloride
(a gift from the National Institute of Drug Administration
Chemical Synthesis and Drug Supply Program) was dissolved in 0.9% saline. All drugs were administered subcutaneously. In the first two experiments (from CAR to
PCP), we tested three doses of HAL (0.03, 0.05, and 0.10
mg/kg) and OLZ (0.5, 1.0, and 2.0 mg/kg). At these
doses, HAL and OLZ produced a comparable level of disruption on avoidance responding, which is considered a
validated behavioral index of antipsychotic action (Li et
al., 2004a, 2007, 2009a, 2009b; Mead and Li, 2010). Furthermore, both drugs at these doses give rise to 50-80% striatal dopamine D2 occupancy in rats, which is comparable
with values observed in schizophrenic patients (Kapur et
al., 2005). On the basis of the findings from the first two
experiments and our published work (Sun et al., 2009), we
tested HAL at 0.05 mg/kg and OLZ at 1.0 mg/kg in the
last two experiments (from PCP to CAR) because they induce a robust sensitization effect in the PCP hyperlocomotion model (Sun et al.., 2009).
Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom designed
and manufactured by Med Associates (St. Albans, Vermont, USA) were used. Each box was housed in a ventilated, sound-insulated isolation cubicle (96.52-cm width
× 35.56-cm diameter × 63.5-cm height). Each box was 64cm long, 30-cm high (from grid floor), and 24-cm wide,
and was divided into two equal-sized compartments
by a partition with an arch-style doorway (15-cm high
x 9-cm wide at base). A barrier (4-cm high) was placed
between the two compartments, so the rats had to jump
from one compartment to the other. The grid floor consisted of 40 stainless-steel rods with a diameter of 0.48
cm, spaced 1.6 cm apart center to center, through which
a scrambled foot shock [unconditioned stimulus (US),
0.8 mA, maximum duration: 5 s] was delivered by a constant current shock generator (Model ENV-410B) and
scrambler (Model ENV-412). The rat’s location and crossings between compartments were monitored by a set of
16 photobeams (ENV-256-8P) affixed at the bottom of the
box (3.5 cm above the grid floor). Illumination was provided by two house lights mounted at the top of each
compartment. The conditioned stimulus (CS; i.e., 76 dB
white noise) was produced by a speaker (ENV 224 AMX)
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mounted on the ceiling of the cubicle, centered above the
shuttle box. Background noise (approximately 74 dB) was
provided by a ventilation fan affixed at the top corner of
each isolation cubicle. All training and testing procedures
were controlled by Med Associates programs running on
a computer.
Motor activity monitoring apparatus
Sixteen activity boxes were housed in a quiet room. The
boxes were 48.3 × 26.7 × 20.3-cm transparent polycarbonate cages, which were similar to the home cages, but were
each equipped with a row of six photocell beams (7.8 cm
between adjacent beams) placed 3.2 cm above the floor of
the cage. A computer detected the disruption of the photocell beams and recorded the number of beam breaks. All
experiments were run during the light cycle.
Experiment 1:Transferability of haloperidol-induced sensitization from the conditioned avoidance response model
to the phencyclidine hyperlocomotion model
This experiment examined whether the sensitization effect induced by repeated HAL treatment in the CAR
model was transferrable to the PCP-induced hyperlocomotion model. The experiment comprised the following
three phases: avoidance training/sensitization induction
in the CAR, sensitization assessment in the PCP hyperlocomotion model, and sensitization reassessment in the
CAR model.
Avoidance training/sensitization induction in the conditioned avoidance response: Seventy-two rats (run in two batches) were
first habituated to the CAR boxes for 2 days (20 min/day).
Then, they were trained for conditioned avoidance responding for 10 sessions over a 2-week period. Each session consisted of 30 trials. Every trial started by presenting a white noise (CS) for 10 s, followed by a continuous
scrambled foot shock [0.8 mA, US, maximum duration = 5
s] on the grid floor. If a rat moved from one compartment
into the other within the 10s of CS presentation, it avoided
the shock and this shuttling response was recorded as
avoidance. If the rat remained in the same compartment
for more than 10s and made a crossing upon receiving the
foot shock, this response was recorded as escape. If the rat
did not respond during the entire 5-s presentation of the
shock, the trial was terminated and escape failure was recorded. The total number of avoidance responses was recorded for each session. Intertrial intervals varied randomly between 30 and 60 s.
At the end of the training session, 59 rats reached the
training criterion ( > 70% avoidance in each of the last
two sessions). They were first matched on avoidance performance on the last training day (i.e., predrug) to create blocks of rats (n = 3–4 rats/block) that were approximately equal in performance. Within each block, they
were then randomly assigned to one of four groups:
HAL, 0.03 mg/kg (HAL 0.03, n = 7); HAL, 0.05 mg/kg
(HAL 0.05, n = 7); HAL, 0.10 mg/kg (HAL 0.10, n= 7); and
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vehicle (VEH, n = 38), and tested daily under the CS-only
(no shock, 30 trials/daily sessions) condition for 5 consecutive days. The CS-only condition was used to control the
possible confound of the number of shocks received and
to exclude any possible relearning effect caused by the
presence of the US. During each drug test, rats were first
injected with HAL or sterile water. One hour later, they
were placed in the CAR boxes and tested. Because of an
error in data collection, data for seven rats were lost (five
VEH rats, one HAL 0.05, and one HAL 0.10). Thus, the final numbers of rats entered into the subsequent drug testing were as follows: HAL 0.03 (n = 7), HAL 0.05 (n = 6),
HAL 0.10 (n = 6), and VEH (n = 33).
Sensitization assessment in the phencyclidine hyperlocomotion
model: One day after the CAR drug testing, rats were habituated to the motor activity testing boxes for 30 min. On
day 2, rats that were previously treated with HAL in the
CAR received the same HAL treatment, followed by PCP
(termed HAL-HAL 0.03 + PCP, HAL-HAL 0.05 + PCP, and
HAL-HAL 0.10 + PCP groups). Rats that were previously
treated with sterile water in the CAR were randomly assigned to five groups: three groups received HAL, followed by PCP (termed VEH-HAL 0.03 + PCP, n = 5; VEHHAL 0.05 + PCP, n = 6; and VEH-HAL 0.10 + PCP, n = 5),
and two groups received sterile water, followed by PCP or
saline (termed VEH-VEH + PCP, n = 8 and VEH-VEH +
VEH, n = 9). During this test, rats were first injected with
HAL or sterile water. Immediately after injection, they
were placed in the motor activity testing boxes for 30 min.
At the end of the 30-min period, rats were taken out and
injected with either VEH (0.9% saline) or PCP (1.6 mg/kg,
subcutaneously) and placed back in the boxes for another
60 min (Sun et al., 2009). Motor activity (number of photobeam breaks) was measured at 5-min intervals throughout
the entire 90-min testing session.
Sensitization reassessment in the conditioned avoidance response:
One day after the PCP hyperlocomotion test, all rats were
returned back to the CAR task and tested drug-free for
one session under the CS-only (no shock) condition and
retrained for one session under the CS-US condition to
bring their avoidance back to the predrug level. A final
challenge test for sensitization was conducted 24 h after
the retraining session, during which all rats were injected
with HAL 0.03 and tested for avoidance performance in
the CS-only condition (30 trials) 1 h later. Table 1 presents
the group information in different phases of Experiment 1.
Experiment 2: Transferability of olanzapine-induced sensitization from the conditioned avoidance response model
to the phencyclidine hyperlocomotion model
This experiment examined whether the sensitization induced by repeated OLZ treatment in the CAR model was
transferrable to the PCP hyperlocomotion model. The basic
procedure was identical to that of Experiment 1, with the
exception that HAL (0.03, 0.05, and 1.0 mg/kg) was
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Table 1. A schematic depiction of the experimental groups formed
at different phases of Experiment 1.
CAR
4 groups

Locomotor activity
8 groups

VEH-VEH + VEH (n=9)
VEH-VEH + PCP (n=8)
VEH (n=33)
VEH-HAL 0.03 + PCP (n=5)
VEH-HAL 0.05 + PCP (n=6)
VEH-HAL 0.10 + PCP (n=5)
HAL 0.03 (n=7) HAL 0.03-HAL 0.03 + PCP
HAL 0.05 (n=6) HAL 0.05-HAL 0.05 + PCP
HAL 0.10 (n=6) HAL 0.10-HAL 0.10 + PCP

CAR
4 groups

VEH-HAL 0.03
HAL 0.03-HAL 0.03
HAL 0.05-HAL 0.03
HAL 0.10-HAL 0.03

Letters in bold indicate the type of treatments administered at different
phases. CAR, conditioned avoidance response; HAL, haloperidol; PCP, phencyclidine;VEH, vehicle.

Table 2. A schematic depiction of the experimental groups formed
at different phases of Experiment 2.
CAR
4 groups

VEH (n=35)
OLZ 0.5 (n=7)
OLZ 1.0 (n=5)
OLZ 2.0 (n=6)

Locomotor activity
8 groups
VEH-VEH + VEH (n=8)
VEH-VEH + PCP (n=7)
VEH-OLZ 0.5 + PCP (n=7)
VEH-OLZ 1.0 + PCP (n=6)
VEH-OLZ 2.0 + PCP (n=7)
OLZ 0.5-OLZ 0.5 + PCP
OLZ 1.0-OLZ 1.0 + PCP
OLZ 2.0-OLZ 2.0 + PCP

CAR
4 groups

VEH-OLZ 0.5
OLZ 0.5-OLZ 0.5
OLZ 1.0-OLZ 0.5
OLZ 2.0-OLZ 0.5

Letters in bold indicate the type of treatments administered at different
phases. CAR, conditioned avoidance response; OLZ, olanzapine; PCP. phencyclidine;VEH, vehicle.

replaced by OLZ (0.5, 1.0, and 2.0 mg/kg). Seventy-two
rats (run in two batches) were used, of which 58 reached
the learning criterion. They were then randomly assigned
to one of the following four groups in the initial CAR test
phase: OLZ 0.5 mg/kg (OLZ 0.5, n = 7), OLZ 1.0 mg/kg
(OLZ 1.0, n = 7), OLZ 2.0 mg/kg (OLZ 2.0, n = 7), and
VEH (n = 37). At the end of the CAR testing phase, data
for five rats were lost (two VEH rats, two OLZ 1.0, and
one OLZ 2.0). Thus, the final numbers for each group entered in the subsequent drug testing were: OLZ 0.5: n =
7; OLZ 1.0: n = 5; OLZ 2.0: n = 6; and VEH: n = 35. In the
PCP hyperlocomotion test phase, the VEH groups were
split into five groups: VEH-OLZ 0.5 + PCP (n = 7), VEHOLZ 1.0 + PCP (n = 6), VEH-OLZ 2.0 + PCP (n = 7), VEHVEH + PCP (n = 7), and VEH-VEH + VEH (n = 8). In the
final sensitization reassessment test, all of the rats were
injected with OLZ 0.5. Table 2 depicts the group information in different phases of Experiment 2.
Experiment 3: Transferability of haloperidol-induced sensitization from the phencyclidine hyperlocomotion model
to the conditioned avoidance response model
This experiment was a mirror experiment to Experiment
1 in the sense that it examined the opposite direction of
sensitization transfer. We examined whether the sensitization-like effect induced by repeated HAL (0.05 mg/
kg, subcutaneously) treatment in the PCP hyperlocomo-
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tion model is transferrable to the CAR model. HAL 0.05
was tested because this dose produces a reliable sensitization effect (see Experiment 1 and Li et al., 2010). The entire
experiment comprised the following three phases: sensitization induction in the PCP hyperlocomotion model,
sensitization assessment in the CAR, and sensitization reassessment in the PCP hyperlocomotion model.
Sensitization induction in the phencyclidine hyperlocomotion mode/.
Thirty-two rats were first handled and habituated to the
avoidance conditioning apparatus for 2 days (30 min/
day) and then trained for 10 consecutive days to acquire
robust conditioned avoidance responding. At the end of
the training phase, 25 rats that had reached the training
criterion were used in the subsequent tests. They were
randomly assigned to the following two groups: HAL
0.05 (n = 8) and VEH (n = 17) groups. On day 1, rats were
habituated in the motor activity boxes for 30 min. On day
2, rats were first injected with HAL (0.05 mg/kg) or VEH
(sterile water) and then immediately placed in the boxes
for 30 min. At the end of the 30-min period, they were
taken out and injected with PCP (3.2 mg/kg) and placed
back in the boxes for another 60 min. This procedure was
repeated for another 4 days (a total of 5 testing days). Our
previous work shows that repeated antipsychotic treatment (e.g. HAL, clozapine, OLZ, etc.) produces a robust
sensitization effect in this PCP model (Sun et al., 2009).
Sensitization assessment in the conditioned avoidance response: One
day after the last (fifth) PCP hyperlocomotion test, all rats
were given a CAR retraining session to bring their avoidance back to the predrug level. One day later, the sensitization assessment test was conducted. During this test, rats
in the VEH group were randomly assigned to two subgroups: VEH-VEH (n = 9) and VEH-HAL 0.03 (n = 8) and
received an injection of sterile water or HAL 0.03, respectively. Rats in the HAL 0.05 group were injected with HAL
0.03 (termed HAL 0.05-HAL 0.03 group). They were then
tested for avoidance performance under the CS-only condition (no shock) for 30 trials 1 h after injection.
Sensitization reassessment in the phencyclidine hyperlocomotion
model. One day after the sensitization test in the CAR, a
final sensitization reassessment test was conducted back
in the PCP locomotor model. All rats were first injected
with HAL 0.03 and then immediately placed in the motor activity boxes for 30 min. At the end of the 30-min period, rats were taken out and injected with PCP (3.2 mg/
kg) and placed back in the boxes for another 60 min. Motor activity was measured at 5-min intervals throughout
the entire 90-min testing session.
Experiment 4:Transferability of olanzapine-induced
sensitization from the phencyclidine hyperlocomotion
model to the conditioned avoidance response model
This experiment was a mirror experiment to Experiment 2.
It followed the same procedure as Experiment 3, with the
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exception that HAL (0.05 mg/kg) was replaced by OLZ
(1.0 mg/kg). Thirty-two rats were used, of which 26 rats
reached the training criterion. They were then randomly
assigned to OLZ 1.0 (n = 9) and VEH (n = 17) and tested
in the PCP hyperlocomotion model for 5 days. During the
CAR test phase, the VEH group was randomly split into
two groups: VEH-VEH (n = 8) and VEH-OLZ 0.5 (n = 9),
and received an injection of sterile water or OLZ 0.5, respectively. Rats in the OLZ 1.0 group received OLZ 0.5. In
the sensitization reassessment test, all rats were administered OLZ 0.5, followed by PCP 3.2 30 min later.
Statistical analysis
All data were expressed as mean ± standard error of
the mean. Data from the five drug testing sessions (e.g.,
avoidance response and PCP-induced motor activity)
were analyzed using a factorial repeated-measures analysis of variance (ANOVA), with the between-subjects
factor being drug group and the within-subjects factor
being test session. One-way ANOVAs, followed by posthoc Tukey honestly significant difference tests (for > 3
groups) were used to identify group differences on a specific testing session. For a two-group comparison, independent-samples t-tests were used. A conventional twotailed level of significance at the 5% level was required.
Results
Experiment 1:Transferability of haloperidol-induced
sensitization from the conditioned avoidance response
model to the phencyclidine hyperlocomotion model
Repeated haloperidol treatment produced a progressively
enhanced disruption of avoidance responding in a dosedependent manner
Figure 1a shows the number of avoidance responses
made by the rats in the four groups during the five drug
sessions. The three HAL groups showed a progressive
across-session decrease in avoidance responding. The
VEH group maintained a high level of avoidance responding throughout this phase. Repeated-measures
ANOVA revealed a significant main effect of group [F(3,
48) = 49.20, P < 0.001] and session [F(4, 192) = 11.64, P<
0.001], and a significant group × session interaction
[F(12, 192) = 3.06, P < 0.001]. Post-hoc tests revealed that
all three HAL groups were significantly different from
the VEH group (all P < 0.001). In addition, the HAL 0.10
group differed significantly from the HAL 0.03 group (P
< 0.001) but not from the HAL 0.05 group.
Haloperidol sensitization did not transfer to the phencyclidine hyperlocomotion model
Figure 1b shows the mean motor activity of the eight
groups of rats during the 60-min test period after saline
or PCP injection. One-way ANOVA revealed a significant
main effect of group [F(7,44) = 4.40, P < 0.001]. Post-hoc
Tukey tests showed that in comparison with the VEHVEH + VEH group, the VEH-VEH + PCP group had a
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significantly higher motor activity (P < 0.001). This PCP
effect was attenuated by HAL pretreatment. In comparison with the VEH-VEH + PCP group, all except HAL
0.10-HAL 0.10 + PCP and VEH-HAL 0.05 + PCP had significantly lower motor activity; all P values were less than
0.05. More importantly, when the pairs of acute and repeated HAL groups were compared (e.g., VEH-HAL 0.05
+ PCP vs. HAL 0.05-HAL 0.05 + PCP), no significant difference was found.
Haloperidol sensitization was detected in the conditioned
avoidance response model and showed a dose-dependent
function
Figure 1c shows the number of avoidance responses during the CS-only, retraining, and sensitization reassessment sessions in the CAR model. In the CS-only session,
HAL 0.03 and HAL 0.05 groups still differed significantly
from the VEH and HAL 0.10 group, [F(3,48) = 8.68, P <
0.001], post-hoc tests with all P values of less than 0.05.
These differences disappeared in the retraining session
[F(3, 48) = 0.14, not significant (NS)]. In the sensitization
reassessment test, all rats were tested under HAL 0.03.
One-way ANOVA showed a significant effect of group
[F(3, 48) = 7.77, P < 0.001]. Post-hoc tests showed that the
HAL 0.10 and HAL 0.05 groups had significantly fewer
avoidances than the VEH group (P < 0.02 and 0.001, respectively), which did not differ significantly from the
HAL 0.03 group.
Experiment 2: transferability of olanzapine-induced
sensitization from the conditioned avoidance response
model to the phencyclidine hyperlocomotion model
Repeated olanzapine treatment produced a progressively
enhanced disruption of avoidance responding in a dosedependent manner
Figure 2a shows the number of avoidance responses
made by the rats in the four groups during the five drug
sessions. The three OLZ groups showed a progressive
across-session decrease in avoidance responding. The
VEH group maintained a high level of avoidance responding throughout this phase. Repeated-measures
ANOVA showed a significant main effect of group,
[F(3, 49) = 59.48, P < 0.001] and session [F(4, 196) = 9.46,
P < 0.001], but no significant group × session interaction [F(12, 196) = 1.44, NS]. Post-hoc tests revealed that
all three OLZ groups were significantly different from
the VEH group (all P < 0.001). In addition, the OLZ 0.5
group differed significantly from the OLZ 1.0 and OLZ
2.0 groups (P < 0.05).
Olanzapine sensitization did not transfer to the phencyclidine hyperlocomotion model
Figure 2b shows the mean motor activity of the eight
groups of rats during the 60-min test period after saline or PCP injection. One-way ANOVA revealed a significant main effect of group [F(7, 49) = 3.41, P < 0.005].
Posthoc tests showed that in comparison with the VEH-
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Figure 1. (a) Effect of repeated haloperidol treatment (0.03, 0.05, and 0.10 mg/kg, subcutaneously, – 60 min) on conditioned avoidance responding. Number of avoidance responses made by the rats in the four groups during the five drug conditioning sessions are expressed as
mean ± standard error of the mean. * P < 0.05 relative to the vehicle (VEH) group. # P < 0.05 relative to the haloperidol (HAL) 0.05 and 1.0
mg/kg groups. (b) Effect of acute haloperidol challenges on phencyclidine-induced hyperlocomotion. Motor activity data are expressed as the
mean number of photobeam breaks. Rats were tested for 60 min after phencyclidine (PCP; 1.6 mg/kg, subcutaneously) injection. * P < 0.05 relative to the VEH+PCP group. (c) Effect of an acute haloperidol challenge (0.03 mg/kg, subcutaneously, – 60 min) on avoidance responding in
rats that were previously treated with haloperidol (0.03, 0.05, and 0.10 mg/kg) or VEH during the sensitization induction phase. The avoidance
data on the CS-only and retraining sessions are also presented for comparison. * P < 0.05 relative to the VEH group. # P < 0.05 relative to the
HAL 0.1 mg/kg group. CS, conditioned stimulus.
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Figure 2. (a) Effect of repeated olanzapine (OLZ) treatment (0.5, 1.0, and 2.0 mg/kg, subcutaneously, – 60 min) on conditioned avoidance responding. Number of avoidance responses made by the rats in the four groups during the five drug conditioning sessions are expressed as
mean ± standard error of the mean. * P < 0.05 relative to the vehicle (VEH) group. # P < 0.05 relative to the OLZ 1.0 and 2.0 mg/kg groups.
(b) Effect of acute OLZ challenges on phencyclidine (PCP)-induced hyperlocomotion. Motor activity data are expressed as the mean number
of photobeam breaks. Rats were tested for 60 min after PCP (1.6 mg/kg, subcutaneously) injection. * P < 0.05 relative to the VEH+PCP group.
(c) Effect of acute OLZ challenge (0.5 mg/kg, subcutaneously, – 60 min) on avoidance responding in rats that were previously treated with
OLZ (0.5, 1.0, and 2.0 mg/kg) or VEH during the sensitization induction phase. The avoidance data on the conditioned stimulus-only and retraining sessions are also presented for comparison. * P < 0.05 relative to the VEH group. # P < 0.05 relative to the OLZ 0.5 mg/kg group. CS,
conditioned stimulus.
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VEH + VEH group, the VEH-VEH + PCP group had a
significantly higher motor activity (P < 0.01). This PCP effect was attenuated by OLZ pretreatment. In comparison
with the VEH-VEH + PCP group, VEH-OLZ 2.0 + PCP, P
= 0.004, and OLZ 2.0-OLZ 2.0 + PCP, P < 0.02, had significantly lower motor activity. More importantly, when the
pairs of acute and repeated HAL groups were compared
(e.g. VEH-OLZ 0.5 + PCP vs. OLZ 0.5-OLZ 0.5 + PCP), no
significant difference was found.
Olanzapine sensitization was detected in the conditioned
avoidance response model and showed a dose-dependent
function
Figure 2c shows the number of avoidance responses during the CS-only, retraining, and sensitization reassessment sessions in the CAR. On the CS-only and retraining
days, no significant group difference was found, CS-only
[F(3, 49) = 2.51, P = 0.07], retraining: [F(3, 52) = 1.44, NS).
In the sensitization reassessment test, all rats were tested
under OLZ 0.5. One-way ANOVA showed a significant
effect of group [F(3, 49) = 10.04, P < 0.001). Post-hoc tests
showed that the OLZ 1.0 and OLZ 2.0 groups, but not
the OLZ 0.5 group, had significantly fewer avoidances
than the VEH group (P < 0.002, P < 0.001, and NS, respectively). The OLZ 0.5 group also differed significantly
from the other two OLZ groups (P < 0.05 vs. OLZ 1.0 and
P < 0.02 vs. OLZ 2.0).
Experiment 3: transferability of haloperidol-induced
sensitization from the phencyclidine hyperlocomotion
model to the conditioned avoidance response model
Repeated haloperidol treatment produced a progressively enhanced inhibition of phencyclidine-induced
hyperlocomotion
Figure 3a shows the mean motor activity of rats that received HAL 0.05 or VEH treatment during the 60-min
daily testing period after PCP injection. Haloperidol treatment progressively enhanced its inhibition of PCP-induced increase in motor activity across the 5 test days.
Repeated-measures ANOVA showed significant main effects of group [F(1, 23) = 71.27, P < 0.001) and session [F(4,
92) = 8.18, P < 0.001], and a significant group × session interaction [F(4, 92) = 7.40, P < 0.001).
Haloperidol sensitization did not transfer to the conditioned avoidance response model
Figure 3b shows the number of avoidance responses on
the last (day 10) training day, the retraining day, and the
sensitization assessment day (challenge test). All groups
had a high level of avoidance response on the 10th training session [F(2, 22) = 0.11, NS] and on the retraining day
[F(2, 22) = 1.48, NS], whereas in the challenge test, the
two HAL groups had significantly lower avoidance levels
than the VEH group. One-way ANOVA revealed a significant main effect of group, [F(2, 22) = 9.93, P < 0.001).
Post-hoc Tukey tests showed that both HAL groups differed significantly from the VEH-VEH group (P < 0.01).
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More importantly, there was no significant difference between the two HAL groups, suggesting that prior HAL
experience in the PCP model did not enhance the behavioral effect of HAL in the CAR model.
Haloperidol sensitization was present in the phencyclidine
hyperlocomotion model
Figure 3c shows the mean motor activity 30 min before
and 60 min after PCP injection during the sensitization reassessment test. All rats received a first injection of HAL
0.03, followed by PCP 3.2. In comparison with the VEH
rats that received HAL for the first time in this model,
rats that had previously received HAL 0.05 (Figure 3a)
exhibited significantly lower motor activity in the first 30
min [t(23) = - 2.92, P = 0.01], and the second 60 min [t(23)
= –3.21, P = 0.005].
Experiment 4: transferability of olanzapine-induced
sensitization from the phencyclidine hyperlocomotion
model to the conditioned avoidance response model
Repeated olanzapine treatment produced a progressively enhanced inhibition of phencyclidine-induced
hyperlocomotion
Figure 4a shows the mean motor activity of rats that received olanzapine 1.0 or VEH treatment during the 60min daily testing period after PCP injection. Olanzapine
treatment progressively enhanced its inhibition of PCPinduced increase of motor activity across the 5 test days.
Repeated-measures ANOVA showed significant main
effects of group [F(1, 24) = 40.65, P < 0.001) and session
[F(4,96) = 3.18, P < 0.02], and a significant group × session
interaction [F(4, 96) = 9.06, P < 0.001).
Olanzapine sensitization did not transfer in the conditioned avoidance response model
Figure 4b shows the number of avoidance responses on
the last (day 10) training day, retraining day, and on
the sensitization assessment day (challenge test). All
groups had a high level of avoidance response on the
10th training session [F(2, 23) = 0.558, NS] and on the
retraining day [F(2, 23) = 0.44 NS], whereas in the challenge test, the two OLZ groups had lower avoidance
levels than the VEH group. One-way ANOVA revealed
a significant main effect of group [F(2, 23) = 4.24, P <
0.05]. Post-hoc Tukey tests showed that the OLZ 1.0-0.5
group differed significantly from the VEH-VEH group
(P = 0.026). Acute OLZ 0.5 decreased the avoidance response, but the effect did not reach a significant level.
Most importantly, there was no significant difference
between the two OLZ groups, suggesting that prior
OLZ experience in the PCP model did not enhance the
behavioral effect of OLZ in the CAR model. However,
the finding that only the OLZ 1.0-0.5 group, but not the
VEH-OLZ 0.5 group, differed significantly from the
VEH-VEH group indicates that there might be some residual effect of OLZ experience, which requires further
verification.
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Figure 3. (a) Effect of repeated haloperidol treatment (0.05 mg/kg, subcutaneously) on phencyclidine (PCP)-induced hyperlocomotion. Motor activity data are expressed as the number of photobeam breaks. Rats were tested for 60 min after PCP (3.2 mg/kg, subcutaneously) injection. * P < 0.05 relative to the vehicle (VEH)+PCP group. (b) Number of avoidance responses made by the rats in the three groups during the
10th training, retraining, and CS-only test sessions (under an acute haloperidol challenge, 0.03 mg/kg, subcutaneously, – 60 min) are expressed
as mean ± standard error of the mean. * P < 0.05 relative to the VEH group. (c) Effect of acute haloperidol challenge (0.03 mg/kg, subcutaneously) on PCP-induced hyperlocomotion during the sensitization reassessment test. Motor activity data are expressed as the number of photo
beam breaks. Rats were tested for 30 min (T30) before and 60 min (T60) after PCP (3.2 mg/kg, subcutaneously) injection. * P < 0.05 relative to
the VEH group. CS, conditioned stimulus.

Olanzapine sensitization was present in the phencyclidine
hyperlocomotion model
Figure 4c shows the mean motor activity in the 30 min
before and 60 min after PCP injection during the sensitization reassessment test. All rats received a first injection of OLZ 0.5, followed by PCP 3.2. In comparison
with the VEH rats that received olanzapine for the first
time in this model, rats that had previously received
OLZ 1.0 (Figure 4a) exhibited significantly lower motor
activity in the first 30 min [t(24) = –3.19, P < 0.005], and

significantly lower motor activity in the second 60 min
[t(24) = –3.71, P < 0.001].
Discussion
Our findings on antipsychotic sensitization induced
by HAL and OLZ in both CAR and PCP hyperlocomotion models are consistent with our previous studies, in
which we showed that repeated HAL and OLZ treatment
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Figure 4. (a) Effect of repeated olanzapine (OLZ) treatment (1.0 mg/kg, subcutaneously) on phencyclidine (PCP)-induced hyperlocomotion.
Motor activity data are expressed as number of photobeam breaks. Rats were tested for 60 min after PCP (3.2 mg/kg, subcutaneously) injection. * P < 0.05 relative to the vehicle (VEH)+PCP group. (b) Number of avoidance responses made by the rats in the three groups during the
10th training, retraining, and conditioned stimulus-only test sessions (under an acute olanzapine challenge, 0.5 mg/kg, subcutaneously, – 60 min)
are expressed as mean ± standard error of the mean. * P < 0.05 relative to the VEH group. (c) Effect of acute OLZ challenge (0.5 mg/kg, subcutaneously) on PCP-induced hyperlocomotion during the sensitization reassessment test. Motor activity data are expressed as number of
photo beam breaks. Rats were tested for 30 min (T30) before and 60 min (T60) after PCP (3.2 mg/kg, subcutaneously) injection. * P < 0.05 relative to the VEH group.

caused a progressive and persistent increase in their effects on avoidance responding and PCP-induced hyperlocomotion (Li et al., 2004b, 2007, 2009a, 2009b, 2010; Mead
and Li, 2010). One unique aspect of this study is that two
distinct animal models of antipsychotic drugs were utilized to examine the phenomenon of antipsychotic sensitization and its contextual and behavioral controls. The
lack of transfer of sensitization was found in both directions and with both drugs, suggesting that it is a general

feature of antipsychotic action, rather than an artifact of
any specific models or drugs.
The present study extended our work in the following
four directions. First, it showed that antipsychotic sensitization in the PCP hyperlocomotion model could also be
assessed in the same way as in the CAR model, which is
also the typical setup used to assess psychomotor sensitization (Anagnostaras and Robinson, 1996; Pierce and
Kalivas, 1997; Robinson et al., 1998). That is, the expres-
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sion of antipsychotic sensitization could be examined in
a later challenge test during which all subjects are tested
under the same antipsychotic drug treatment. The behavioral sensitization is indicated by the higher inhibition in
the antipsychotic experienced group than in the drug-naive group. In our previous studies, antipsychotic-induced
sensitization was only indicated by the progressively enhanced inhibition of PCP-induced hyperlocomotion during the repeated drug-treatment period (Sun el al., 2009).
The commonality among these different types of sensitization (e.g. psychomotor sensitization and antipsychotic
sensitization) implies that many research techniques, approaches, and knowledge derived from psychomotor sensitization studies might be introduced into the study of
antipsychotic sensitization.
Second, the study provided a novel approach to assess the situational specificity of antipsychotic sensitization. Studies on contextual and behavioral controls of
psychomotor sensitization or tolerance typically compare a “paired” group (a group that receives drug injection in the test environment) with an “unpaired” group
(a group that receives VEH injection in the test environment, and drug in the home cage) in a single model
(Poulos and Hinson, 1982; Amtage and Schmidt, 2003).
The situational specificity of psychomotor sensitization
is indicated by the finding that it is expressed only in the
“paired” group but not in the “unpaired” group (Robinson et al., 1998). Our previous work used a similar approach and demonstrated that within the CAR model,
antipsychotic sensitization was indeed context dependent (Li et al., 2009a). We found that rats that received
HAL (0.05 mg/kg) or OLZ (1.0 mg/kg) and tested for
avoidance (i.e., the “paired” group) exhibited a progressive enhanced decrease in avoidance responding, indicative of the antipsychotic sensitization effect, whereas
rats that received these drugs in their home cages but
tested for avoidance under VEH (i.e., the “unpaired”
group) did not. The present study suggested that it is
useful to use two different behavioral models to assess
the situational specificity of antipsychotic sensitization.
In comparison with the traditional one-model approach,
this two-model approach is advantageous in revealing
multiple sources of controls of antipsychotic sensitization. Besides distinctive contextual cues, topographically
different behavioral response patterns (i.e., avoidance
response to a sound and PCP-induced increase in motor activity) certainly play a role in this process (Ohmori
et al., 2000). This may explain the rather robust and complete situational control of antipsychotic sensitization
in this study. However, one limitation of this approach
is its inability to determine the relative contributions of
contextual cues and behavioral responses toward the development and expression of antipsychotic sensitization.
Future work utilizing both approaches is needed to address this question.
Third, the study extended the context-dependent sensitization phenomenon involving antipsychotics from
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HAL-induced catalepsy (Lanis and Schmidt, 2001; Amtage and Schmidt, 2003; Klein and Schmidt, 2003) to subject behavioral responses relevant to human psychosis
and to other antipsychotic drugs. Amtage and Schmidt
(2003) and Klein and Schmidt (2003) have reported that
intermittent HAL treatment and repeated catalepsy testing caused an intensification of catalepsy over time and
this intensification was completely context specific, as
context changes abolished catalepsy sensitization. In the
present study, we demonstrated that sensitization induced by the atypical drug OLZ in the CAR and PCP hyperlocomotion models was also highly situation specific,
suggesting that this feature of antipsychotic sensitization
may cut across different groups of antipsychotic drugs
and may be a universal feature reflecting the therapeutic
effects of antipsychotic drugs.
Finally, this study called attention to the issue of possible connections among various animal models of antipsychotic drug action. In preclinical psychopharmacology, there are many diverse groups of animal models
of antipsychotic activity, such as prepulse inhibition of
acoustic startle, latent inhibition, amphetamine-induced
and PCP-induced hyperlocomotion, the paw test, and so
on (Weiner and Feldon, 1994; Kilts, 2001; Geyer and Ellenbroek, 2003). Often, these models are utilized independently without much attention paid to their possible
relationships. As they all claim to be able to detect antipsychotic activity, one important issue is how they are related and whether it is possible to use one model to crossvalidate another. The present study suggests a way to
explore this issue.
As the context-dependent feature of antipsychotic sensitization resembles that found in psychomotor sensitization (Vezina et al., 1989; Stewart and Vezina, 1991; Anagnostaras and Robinson, 1996; Browman et al., 1998;
Robinson et al., 1998; Anagnostaras et al., 2002) and tolerance (Siegel, 1978; Poulos et al., 1981; Siegel et al., 2000),
the conceptualization of antipsychotic sensitization and
its situational specificity can gain insights from the theoretical accounts of behavioral sensitization and tolerance.
On the basis of the present study, our previous work (Li
et al., 2004b, 2007, 2009a, 2009b, 2010; Mead and Li, 2010)
and the work of others (Stewart and Vezina, 1991; Anagnostaras et al., 2002), we propose that three psychological
and neuronal processes may govern the induction and expression of antipsychotic sensitization and its contextual
and behavioral controls.
First, repeated antipsychotic treatment may induce
an unconditioned and nonassociative enhancement of
behavioral effects (i.e., sensitization) attributable to the
direct pharmacological action of a drug. There is substantial evidence indicating that chronic antipsychotic
treatment alters the neurochemical systems that mediate
their behavioral activating effects (Meltzer et al., 1989;
Konradi and Heckers, 2001; Meltzer et al., 2003; Schmitt
et al., 2003; Lieberman et al., 2008). Many antipsychotic
sensitization-related brain changes have been identified
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and they are observed in the absence of any associative
influence. For example, it has been shown that repeated
antipsychotic treatment changes the density and sensitivity of dopamine D2 receptors (Seeman, 2000; Samaha
et al., 2007, 2008), 5-HT2A and 5-HT2C receptors (Buckland et al., 1997) and other receptors (McCoy et al., 1996;
Marcus et al., 1997; Nudmamud and Reynolds, 2001;
Tooney et al., 2005). Our own work on the neurochemical basis of the antipsychotic sensitization induction in
the CAR model also indicates a role for dopamine and
serotonin receptors in this process (Li et al., 2010, 2011b).
We found that with 2,5-dimethoxy-4-iodo-amphetamine, a selective 5-HT2A/2C serotonergic receptor agonist, but not quinpirole, a selective D2/D3 dopaminergic
receptor agonist, attenuated HAL sensitization of avoidance responding, whereas pretreatment with quinpirole,
but not 2,5-dimethoxy-4-iodo-amphetamine, attenuated
the effect of OLZ. These findings suggest that the induction of HAL sensitization may be mediated by 5-HT2A/2C
blockade-initiated neuroplasticity, whereas the induction of OLZ sensitization may be mediated by D2/D3
blockade-initiated neuroplasticity. Psychologically, our
previous work suggests that antipsychotic drugs disrupt avoidance responding by progressively attenuating the motivational salience of the CS (Li et al., 2007).
This hypothesis can also be utilized to explain the sensitization effect in the PCP hyperlocomotion model. The
PCP model can be thought of as reflecting an exaggerated exploration of the environment as a consequence
of the increased motivational salience of environmental stimuli (Wise and Bozarth, 1987). Therefore, the antipsychotic-induced progressively enhanced inhibition of
PCP-induced hyperlocomotion can be considered a consequence of the weakened motivational salience of environmental stimuli by antipsychotic treatment.
Second, distinct contextual cues (e.g. environmental
stimuli, interoceptive drug cue, etc.) and altered behavioral responses in each model may develop an association with unconditional drug effects through a Pavlovian conditioning process, and thus become excitatory
conditional stimuli. These contextual cues and behavioral variables acquire the ability to elicit an antipsychotic-like effect by themselves and may potentiate the
sensitized response in an expected situation. The lack of
transfer of sensitization between models could be attributed to the disruption of the excitatory controls of contextual cues and behaviors, as the across-model transfer
entails changes not only in context but also in behavioral responses. Contextual changes may consist of stimulus addition (inclusion of novel contextual stimuli) as
well as stimulus subtraction (loss of originally trained
context). Substantial evidence suggests that contextual
cues, especially the environmental stimuli and interoceptive drug state, can serve as conditional stimuli and
become associated with unconditional drug effects (as
US) by a Pavlovian conditioning process after being repeatedly paired with a drug (Siegel et al., 2000). In our
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own lab, we have shown that rats that had been repeatedly treated with HAL (0.05 mg/kg, subcutaneously)
and clozapine (20 mg/kg, subcutaneously) during the
acquisition or the extinction phase of the CAR model
still showed a decreased avoidance response when they
were tested 2 days later in the absence of the drug (Li et
al., 2004b). In the present study, we also observed that
rats previously treated with HAL (0.03 and 0.05 mg/kg)
made fewer avoidance responses on the CS-only drugfree test. These findings imply that the CAR testing environment exerted an antipsychotic-like effect on avoidance responding. Future work is needed to specify the
magnitude of the impact of contextual cues on antipsychotic sensitization.
Finally, contextual stimuli and different topographic
behavioral responses may serve as occasion setters to
modulate the manifestation of sensitized responses. Occasion setters are a class of conditional stimuli that do
not themselves elicit an antipsychotic-like effect, but
modulate the ability of other stimuli to elicit responses
(Holland, 1989). A change of testing models may cause
a disruption of the occasion-setting property of contextual stimuli and behavioral responses, which leads to
the disruption of across-model transfer of antipsychotic
sensitization. It is well documented that contextual cues
and altered behavioral responses can function as occasion setters to modulate the expression of psychomotor
sensitization involving psychostimulants (Smith, 1991;
Anagnostaras and Robinson, 1996; Lanis and Schmidt,
2001; Sripada et al., 2001). Our previous work also provides evidence supporting this account. For example, in
the study by Mead and Li (2010), we showed that rats intermittently treated with OLZ (1.0 mg/kg, subcutaneously) or HAL (0.03 mg/kg, subcutaneously) on the first
day of a 3-day cycle for seven cycles exhibited a progressive across-session decline in avoidance responding (i.e.,
antipsychotic sensitization), despite the fact that they exhibited a comparable high level of avoidance responding
on the third day of each cycle during the drug-free retraining session. As we have previously discussed (Mead
and Li, 2010), an antipsychotic drug and altered behavioral responses can act as an occasion setter (Maes and
Vossen, 1997), which sets the condition in which rats behave on the basis of their previous drug experience in
the avoidance testing context, or it may directly imprint
the brain to create a drug “memory trace” about avoidance responding under drug (the neural basis of antipsychotic sensitization). One prediction on the basis of this
drug-dependent sensitization mechanism is that even if
the drug has been stopped and the avoidance responding has fully reverted to the predrug level, during the
next exposure to antipsychotic treatment, the subjects
with a previous drug experience should show a greater
response, a prediction that was confirmed for both OLZ
and risperidone (Mead and Li, 2010).
In summary, the present study used a novel twomodel approach and provided strong evidence for the
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contextual and behavioral controls of antipsychotic sensitization. Our work also revealed three neuropsychological processes that are potentially critical for the induction and expression of antipsychotic sensitization,
emphasizing the long-term neuroplasticities due to
chronic drug treatment and the role of contextual cues
and behaviors functioning as conditional stimuli and
occasion setters. Insofar as this effect is important for
maintaining antipsychotic effects over time, understanding the neurobiological and psychological mechanisms
behind it would greatly enhance our knowledge of the
psychological and neurochemical nature of antipsychotic treatment in the clinic.
Acknowledgments — This study was funded in part by the
National Institute of Mental Health Grant (R01MH085635) to
Professor Ming Li. Dr. Chen Zhang was supported by a faculty development grant from Shanghai Jiao Tong University
School of Medicine. The authors thank Natashia Swalve and
Ms. Heidi Gonzalez for their editorial help.

References
Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset
hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235.
Agid O, Seeman P, Kapur S (2006). The “delayed onset” of antipsychotic action: An idea whose time has come and gone. J Psychiatry Neurosci 31:93-100.
Amtage J, Schmidt WJ (2003). Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behav
Pharmacol 14:563-567.
Anagnostaras SG, Robinson TE (1996). Sensitization to the psychomotor stimulant effects of amphetamine: Modulation by associative learning. Behav Neurosci 110:1397-1414.
Anagnostaras SG, Schallert T, Robinson TE (2002). Memory processes governing amphetamine-induced psychomotor sensitization. Neuropsychopharmacology 26:703-715.
Browman KE, Badiani A, Robinson TE (1998). Modulatory effect of
environmental stimuli on the susceptibility to amphetamine
sensitization: A dose-effect study in rats. J Pharmacol Exp Ther
287:1007–1014.
Buckland PR, D’Souza U, Maher NA, McGuffin P (1997). The effects
of antipsychotic drugs on the mRNA levels of serotonin 5HT2A
and 5HT2C receptors. Brain Res Mol Brain Res 48:45-52.
Emsley R, Rabinowitz J, Medori R (2006). Time course for antipsychotic treatment response in first-episode schizophrenia. Am J
Psychiatry 163:743-745.
Geyer MA, Ellenbroek B (2003). Animal behavior models of the
mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol BioI Psychiatry 27:1071-1079.
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology (Berl) 156:117-154.
Gleason SO, Shannon HE (1997). Blockade of phencyclidine-induced
hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology
(Berl) 129:79-84.

in

B e h av i o u r a l P h a r m ac o l o g y 23 (2012)

Glick ID, Shkedy Z, Schreiner A (2006). Differential early onset of
therapeutic response with risperidone vs. conventional anti psychotics in patients with chronic schizophrenia. Int Clin Psychopharmacol 21:261-266.
Holland PC (1989). Transfer of negative occasion setting and conditioned inhibition across conditioned and unconditioned stimuli. J
Exp Psychol Anim Behav Process 15:311-328.
Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B (2005).
Evidence for onset of antipsychotic effects within the first 24
hours of treatment. Am J Psychiatry 162:939-946.
Kilts CD (2001). The changing roles and targets for animal models of
schizophrenia. BioI Psychiatry 50:845-855.
Klein A, Schmidt WJ (2003). Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or
chronic dopamine deficiency. Behav Pharmacol 14:49-53.
Konradi C, Heckers S (2001). Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia. BioI Psychiatry 50:729-742.
Lanis A, Schmidt WJ (2001). NMDA receptor antagonists do not
block the development of sensitization of catalepsy, but make its
expression state-dependent. Behav Pharmacol 12:143-149.
Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005). Early-onset hypothesis of antipsychotic drug action: A hypothesis tested,
confirmed and extended. BioI Psychiatry 57:1543-1549.
Li M, Davidson P, Budin R, Kapur S, Fleming AS (2004a). Effects of
typical and atypical antipsychotic drugs on maternal behavior in
postpartum female rats. Schizophr Res 70:69-80.
Li M, Parkes J, Fletcher PJ, Kapur S (2004b). Evaluation of the motor
initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Biochem Behav 78:811-819.
Li M, Fletcher PJ, Kapur S (2007). Time course of the antipsychotic
effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272.
Li M, He W, Mead A (2009a). An investigation of the behavioral
mechanisms of antipsychotic action using a drug-drug conditioning paradigm. Behav Pharmacol 20:184-194.
Li M, He W, Mead A (2009b). Olanzapine and risperidone disrupt
conditioned avoidance responding in phencyclidine-pretreated
or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus. Behav Pharmacol
20:84-98.
Li M, Sun T, Zhang C, Hu G (2010). Distinct neural mechanisms underlying acute and repeated administration of antipsychotic
drugs in rat avoidance conditioning. Psychopharmacology (Berl)
212:45-57.
Li M, He E, Volf N (2011a). Time course of the attenuation effect of
repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment. Pharmacol Biochem Behav 98:559-569.
Li M, Sun T, Mead A (2011b). Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing
5-HT(2A/2C) receptors. J Neural Transm (advance online).
Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE,
Mane CE, et al. (2008). Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60:358-403.
Maes JH, Vossen JM (1997). Conditional control by midazolam and
amphetamine in a rapid appetitive discrimination procedure. Eur
J Pharmacol 319:5-11.
Marcus MM, Nomikos GG, Malmerfelt A, Zachrisson O, Lindefors N,
Svensson TH (1997). Effect of chronic antipsychotic drug treatment on preprosomatostatin and preprotachykinin A mRNA

C o n t ro l

o f a n t i p s y c h ot i c s e n s i t i z at i o n i n d u c e d b y h a l o p e r i d o l a n d o l a n z a p i n e

levels in the medial prefrontal cortex, the nucleus accumbens
and the caudate putamen of the rat. Brain Res Mol Brain Res
45:275-282.
McCoy L, Cox C, Richfield EK (1996). Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring
form of AMPA receptor in rat brain. Eur J Pharmacol 318:41-45.
Mead A, Li M (2010). Avoidance-suppressing effect of antipsychotic
drugs is progressively potentiated after repeated administration: An interoceptive drug state mechanism. J Psychopharmacol
24:1045-1053.
Meltzer HY, Matsubara S, Lee JC (1989). The ratios of serotonin2
and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol BuIl 25:390-392.
Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors:
Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
Nudmamud S, Reynolds GP (2001). Increased density of
glutamate/N-methyl-D-aspartate receptors in superior temporal
cortex in schizophrenia. Neurosci Lett 304:9-12.
Ohmori T, Abekawa T, Ito K, Koyama T (2000). Context determines
the type of sensitized behaviour: A brief review and a hypothesis on the role of environment in behavioural sensitization. Behav
Pharmacol 11:211-221.
Pierce RC, Kalivas PW (1997). A circuitry model of the expression
of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25:192-216.
Poulos CX, Hinson R (1982). Pavlovian conditional tolerance to haloperidol catalepsy: Evidence of dynamic adaptation in the dopaminergic system. Science 218:491-492.
Poulos CX, Hinson RE, Siegel S (1981). The role of Pavlovian processes in drug tolerance and dependence: Implications for treatment. Addict Behav 6:205-211.
Raedler TJ, Schreiner A, Naber D, Wiedemann K (2001). Early onset
of treatment effects with oral risperidone. BMC Psychiatry 7:4.
Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: A review
and evaluation of animal models of amphetamine psychosis. Brain
Res 396:157-198.
Robinson TE, Browman KE, Crombag HS, Badiani A (1998). Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 22:347-354.
Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007). “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986.
Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega IN, Kapur
S (2008). Less is more: Antipsychotic drug effects are greater
with transient rather than continuous delivery. Biol Psychiatry
64:145-152.

79

Schmitt A, Zink M, Muller B, May B, Herb A, Jatzko A, et a/. (2003).
Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res
28:235-241.
Seeman P (2000). Antipsychotic drugs, dopamine D2 receptors and
schizophrenia. In: Lidow MS, ed., Neurotransmitter receptors in actions of antipsychotic medications. Boca Raton, Florida: CRC Press
LLC. pp. 43-63.
Siegel S (1978). Pavlovian conditioning analysis of morphine tolerance. NIDA Res Monogr 18:27-53.
Siegel S, Baptista MA, Kim JA, McDonald RV, Weise-Kelly L (2000).
Pavlovian psychopharmacology: The associative basis of tolerance. Exp Clin Psychopharmacol 8:216-293.
Smith J B (1991). Situational specificity of tolerance to decreased operant responding by morphine and I-nantradol. Psychopharmacology (Berl) 103:115-120.
Sripada S, Gaytan O, Swann A, Dafny N (2001). The role of MK-801
in sensitization to stimulants. Brain Res Brain Res Rev 35:97-114.
Stewart J,Vezina P (1991). Extinction procedures abolish conditioned
stimulus control but spare sensitized responding to amphetamine. Behav Pharmacol 2:65-71.
Sun T, Hu G, Li M (2009). Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced
hyperlocomotion: Relevance to animal models of antipsychotic
drugs. Eur J Pharmacol 602: 334-342.
Tarsy O, Baldessarini RJ (1974). Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 13:927-940.
Tooney PA, Anderson WB, Lynch-Frame A, Chahl LA (2005). The effects of haloperidol treatment on the distribution of NK1 receptor immunoreactive neurons in guinea pig brain. Neurosci Lett
383:155-159.
Vezina P, Stewart J (1984). Conditioning and place-specific sensitization of increases in activity induced by morphine in the VTA.
Pharmacol Biochem Behav 20:925-934.
Vezina P, Giovino AA, Wise RA, Stewart J (1989). Environment-specific cross-sensitization between the locomotor activating effects of morphine and amphetamine. Pharmacol Biochem Behav
32:581-584.
Weiner I, Feldon J (1994). The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action:
Comment on Dunn, Atwater and Kilts (Psychopharmacology
1993;112:315-323). Psychopharmacology (Berl) 116:319-381.
Wise RA, Bozarth MA (1987). A psychomotor stimulant theory of
addiction. Psychol Rev 94:469-492.

